NCT05979168 Effectiveness and Adoption of the TelTex4BP Intervention Among Adults With Hypertension in Nepal
| NCT ID | NCT05979168 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Department of Public Health |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-11-02 |
| Primary Completion | 2026-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-11-02 with a primary completion date of 2026-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Despite evidence of preventing cardiovascular disease (CVD) risk through lifestyle changes, many patients with hypertension (HTN) do not comply with this and suffer from CVD and other complications. A previous study using a structured lifestyle intervention program has reported a 14% decrease in the 10-year risk of developing CVD at one year among hypertensive and diabetes patients. Low and Middle-Income countries (LMICs) struggle with a shortage of health workers to deliver such interventions. In this context, mobile phones can contribute to bridging this gap by incorporating them into the health system for health intervention delivery. There is a need to develop contextual mHealth intervention adapted to local needs and culture and test its effectiveness in LMIC settings like Nepal. Our previous small-scale pilot mHealth (text messages) study reported promising evidence in reducing blood pressure among hypertensive patients in the intervention arm \[adjusted reduction in systolic blood pressure (BP) -6.50 (95% CI, -12.6; -0.33) and diastolic BP -4.60 (95% CI, -8.16; -1.04)\], with a greater proportion achieving target BP (70% vs 48% in the control arm, p = 0.006)\] and improving treatment compliance (p \< 0.001) in Nepal. This finding supports the expansion to a large-scale trial of a structured mHealth intervention to see its long-term effectiveness and sustainability for patients with HTN to improve BP control and reduce CVD risk. Hence, this study aims to assess the effectiveness of a behavioural intervention through mHealth (telephone/mobile phone calls and text messages) informed by the RE-AIM framework for improving blood pressure control among patients with hypertension in a hospital (Manamohan Cardiothoracic Vascular and Transplant Center) of Kathmandu, Nepal.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of hypertension * Currently receiving/prescribed blood pressure-lowering medication for more than three months * With uncontrolled blood pressure (\>130/80mm of Hg) * Should have access to a mobile phone * Able to read text messages ( by themselves/with the help of family) Exclusion Criteria: * Diagnosed with myocardial infarction, stroke, and kidney failure * Severe mental illness, cognitive impairment * Pregnant women or in the postpartum period
Contact & Investigator
Buna Bhandari Bhattarai, PhD
PRINCIPAL INVESTIGATOR
Indiana University
Frequently Asked Questions
Who can join the NCT05979168 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05979168 currently recruiting?
Yes, NCT05979168 is actively recruiting participants. Contact the research team at buna.bhandari@gmail.com for enrollment information.
Where is the NCT05979168 trial being conducted?
This trial is being conducted at Kathmandu, Nepal, Kathmandu, Nepal.
Who is sponsoring the NCT05979168 clinical trial?
NCT05979168 is sponsored by Central Department of Public Health. The principal investigator is Buna Bhandari Bhattarai, PhD at Indiana University. The trial plans to enroll 500 participants.